Skip to content

Sorry, the page you are looking for is no longer available

The Medicines Guides database is no longer being published. If you are looking for information about medicines you might find what you are looking for on this website.

If the suggestions below are not what you were looking for, enter the name of a medicine in the search box above and click ‘Go’.

This website, the eMC, is a medicines information database of documents approved by the UK or European medicines regulators. It includes Patient Information Leaflets (PILs) the paper inserts that are included in the pack with a medicine, which are written specifically for the public. 

Discontinued Discontinued Black Triangle Black Triangle Show history Show history

MEDICINE NAME

ACTIVE INGREDIENTS

COMPANY NAME

 

Pil
Updated 21-Dec-2016 Show History
glycopyrronium bromide , neostigmine metilsulfate Concordia International - formerly AMCo
Pil
Updated 05-Jul-2016 Show History
glycopyrronium bromide , neostigmine metilsulfate Martindale Pharma
Pil
Updated 13-Mar-2017 Show History
glycopyrronium bromide , Colonis Pharma Ltd
Pil
Updated 07-Oct-2016 Show History
glycopyrronium bromide Accord Healthcare Limited
Pil
Updated 10-Oct-2016 Show History
glycopyrronium bromide Martindale Pharma
Pil
Updated 22-Sep-2016 Show History
glycopyrronium bromide Concordia International - formerly AMCo
Pil
Updated 22-Sep-2016 Show History
glycopyrronium bromide Concordia International - formerly AMCo
Pil
Updated 09-Aug-2017 Show History black triangle
glycopyrronium bromide Novartis Pharmaceuticals UK Ltd
Pil
Updated 18-Apr-2017 Show History
glycopyrronium bromide , glycopyrrolate Proveca Limited
Pil
Updated 07-Aug-2017 Show History
beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide Chiesi Limited
Pil
Updated 13-Nov-2017 Show History black triangle
glycopyrronium bromide , indacaterol maleate Novartis Pharmaceuticals UK Ltd

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue